RSV F
Reaktivität: Respiratory Syncytial Virus (RSV)
EIA, PrA
Wirt: Maus
Monoclonal
unconjugated
Applikationshinweise
Optimal working dilution should be determined by the investigator.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1.0 mg/mL
Adams, Bonzel, Kovacevic, Mayatepek, Hoehn, Vogel: "Palivizumab-resistant human respiratory syncytial virus infection in infancy." in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 51, Issue 2, pp. 185-8, (2010) (PubMed).
Eckardt-Michel, Lorek, Baxmann, Grunwald, Keil, Zimmer: "The fusion protein of respiratory syncytial virus triggers p53-dependent apoptosis." in: Journal of virology, Vol. 82, Issue 7, pp. 3236-49, (2008) (PubMed).
Mason, Lawetz, Gaudette, Dô, Scouten, Lagacé, Simoneau, Liuzzi: "Polyadenylation-dependent screening assay for respiratory syncytial virus RNA transcriptase activity and identification of an inhibitor." in: Nucleic acids research, Vol. 32, Issue 16, pp. 4758-67, (2004) (PubMed).
Target
RSV Fusion Protein (RSV F)
(Respiratory Syncytial Virus Fusion Protein (RSV F))
Andere Bezeichnung
RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEIN (RSV F Produkte)